Inotrem Announces Positive Outcome of its Phase II ASTONISH Trial in Septic Shock Patients Demonstrating Efficacy of Nangibotide
ASTONISH confirms the therapeutic potential of nangibotide in septic shock patients with excessive activation of the TREM-1 pathway ASTONISH confirms that the soluble TREM-1 biomarker predicts response to nangibotide treatment PARIS–(BUSINESS WIRE)–#biotech–Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory syndromes, disclosed for the first time today at the … [Read more…]
